CompletedPhase 2NCT00075439

Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors

Studying Zollinger-Ellison syndrome

Last synced from ClinicalTrials.gov May 5, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: National Cancer Institute (NCI)
Principal Investigator: Timothy Hobday, M.D
Mayo Clinic
Intervention: gefitinib(drug)
Enrollment: 90 enrolled
Eligibility: 18 years · All sexes
Timeline: 2003

Study locations (1)

Mayo Clinic, Rochester, Minnesota, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00075439 on ClinicalTrials.gov

Other trials for Zollinger-Ellison syndrome

Additional recruiting or active studies for the same condition.

ACTIVE NOT RECRUITINGPHASE2NCT01824875
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
ECOG-ACRIN Cancer Research Group

See all trials for Zollinger-Ellison syndrome →

← Back to all trials